This article is a collaboration between 鶹ý and:
August in Barcelona: hot. And so may be the news there at the European Society of Cardiology meeting, as the late-breaking have been announced.
Topline results released on the CANTOS trial indicated that the anti-inflammatory autoimmune drug canakinumab (Ilaris) reduced the risk of major adverse cardiovascular events among MI survivors with elevated high-sensitivity C-reactive protein. Main trial results are slated for the opening .
Also at that session are the data, both the main results (comparing rivaroxaban [Xarelto] with or without aspirin against aspirin alone in prevention of heart attacks, stroke or cardiovascular death in patients with coronary or peripheral artery disease) and a substudy looking at coronary and peripheral artery disease patients separately.
Other trials slated for presentation in Hot Line sessions include:
- : Renal denervation in uncontrolled hypertension without any antihypertensive medication
- : A randomized trial of supplemental oxygen for suspected acute MI
- RACE 3: Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure
- CASTLE-AF: Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation
- EMANATE: Apixaban versus conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion
- : Web-based clinical decision support system that computerizes atrial fibrillation guidelines compared with standard primary care
- : A randomized trial of a combined screening program for abdominal aortic aneurysm, peripheral artery disease, and hypertension in older men
- REHEARSE-AF: Remote heart rhythm sampling with the AliveCor device to screen for atrial fibrillation
Airway management during CPR, adding left atrial appendage closure to open heart surgery, an ambulatory blood pressure monitoring substudy of the PRECISION trial are also in the lineup.
Notably, the last of the phase III CETP inhibitor trials, the pivotal REVEAL trial for anacetrapib, is slated to be released in the final Hot Line session of the conference. The conference also features a a Mendelian randomization comparison of CETP inhibitors and statins.